Stimulates Human Clara Cell Secretory Protein
Production by Human Airway Epithelial Cells
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Clara cell secretory protein (CCSP), or CC10, is an inhibitor of secretory phospholipase A2 which may be
produced by phagocytic cells and by a variety of other cells in the airway. Tumor necrosis factor-
(TNF-
)
is capable of activating phospholipases and inducing the expression of a variety of genes in the airway epithelium which may modulate the airway inflammatory response. Therefore, it was of interest to determine
whether this proinflammatory cytokine could induce the production of a counterregulatory protein such as
CCSP which might modulate the production of eicosanoid mediators in the airway. Using a human bronchial epithelial cell line (BEAS-2B), CCSP messenger RNA (mRNA) levels were detected by ribonuclease protection assay. TNF treatment of these cells increased CCSP mRNA levels in a time- and dose-dependent
manner. The CCSP mRNA level increased in response to TNF-
(20 ng/ml) stimulation after 8 to 36 h with
the peak increase at 18 h. Immunoblotting of CCSP protein released into the culture media demonstrated
that TNF-
induced the synthesis and secretion of CCSP protein in a time-dependent manner over 8 to 18 h.
The results of a CCSP reporter gene activity assay, nuclear run-on assay, and CCSP mRNA half-life assay
indicated that the TNF-
-induced increases in CCSP gene expression are regulated at the post-transcriptional level. We conclude that TNF-
induces airway epithelial cell expression of human CCSP protein and
may modulate airway inflammatory responses in this manner.
| |
Introduction |
|---|
|
|
|---|
Clara cell secretory protein (CCSP) (1), or CC10-kD protein (CC10kD), was first named from the apparent molecular mass of this protein in nonreducing sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(2). This protein has been isolated from rat (3, 4), mouse
(5), hamster (6), rabbit (7), and human (2) lung lavage or
tissue. It is also called PCB (polychlorinated biphenyl)
binding protein (4, 8). CCSP is identical to the urinary protein 1 (P1), an
-microprotein isolated from the urine of
patients with tubular proteinuria (9). CCSP consists of two
identical subunits of 70 amino acids joined by two disulfide
bonds (10, 11) and has high homology with the rat and murine CC10-kD protein and rabbit uteroglobin (3, 7, 12).
CCSP is expressed in many non-respiratory organs (16,
17), as well as in airway epithelial cells (2, 18). While
much work has been done on the CCSP gene sequence
(17, 20), derived amino acid sequences (9, 15, 21), and its cellular and tissue distributions (2, 16), the physiologic function of CCSP is still unclear. Andersson and colleagues (22) have suggested that CCSP may function to
bind to calcium, proteins, or other ligands; that the phospholipase A2 (PLA2) inhibition occurs via calcium sequestration; and that the true physiologic function of CCSP is
yet to be determined. The recent work indicates that mice
in which the uteroglobin gene was disrupted have increased serum PLA2 activity and develop glomerulonephritis (23). Because uteroglobin is reported to have immunosuppressive, anti-inflammatory, antiproteinase, anti-PLA2,
and progesterone binding activities (14, 24, 25), CCSP might
represent an important immunomodulatory and anti-inflammatory protein protecting the respiratory tract from exaggerated inflammatory reactions.
Epithelial cells lining the airways act as a protective barrier. It is now recognized that the pulmonary epithelium has other important functions. Epithelial cells may modulate the inflammatory response in the airway through the release of cytokine and lipid mediators (26). Therefore, the airway epithelium may play an active role in initiating, amplifying, or modulating airway inflammation (27). It is in this context that we were interested in the study of cytokine-stimulated CCSP gene expression and translation in human bronchial epithelial cells.
The tumor necrosis factor (TNF) "family" includes two
structurally and functionally related proteins, TNF-
and
TNF-
. TNF-
is a multifunctional cytokine, produced
mainly by monocytes and macrophages (28), that has a
wide range of activities in various cell types (29) and
plays a prominent role in host-defense responses to a variety of stimuli (32). TNF induces the production of prostaglandins, leukotrienes, and platelet-activating factor, which
serve as potent lipid inflammatory mediators in many types of cells (33). TNF-
also stimulates PLA2 enzyme activity and cytosolic PLA2 (cPLA2) gene expression (37) in
the airway epithelium. Because TNF-
can induce gene expression in airway epithelial cells and may modulate the inflammatory response in the airway, we studied the effect of
this cytokine on CCSP messenger RNA (mRNA) expression and CCSP protein synthesis in airway epithelial cells.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Culture
BEAS-2B cells, a human bronchial epithelial cell line transformed by an adenovirus 12-SV40 virus hybrid, were a generous gift from Drs. J. E. Lechner and C. Harris (National Cancer Institute, National Institutes of Health, Bethesda, MD). The cells were cultured in 175-cm2 tissue-culture flasks (Falcon/Becton Dickinson, Oxnard, CA) which were precoated with a thin layer of rat-tail Type I collagen (Collaborative Research, Bedford, MA) using the serum-free, hormonally defined culture medium LHC-8 (Biofluids, Inc., Rockville, MD). Experiments were performed when the cells reached 80% confluence (approximately 30 million cells/flask).
Normal human tracheobronchial epithelial (NHTBE) cells (Clonetics Corp., San Diego, CA) were seeded into six-well plastic tissue culture dishes at 1 × 104 cells/well. The tissue culture dishes were precoated with a thin layer of rat-tail Type I collagen (Collaborative Research). NHTBE cells were grown in bronchial epithelial growth medium (Clonetics Corp.). Experiments were done when the cells reached 80% confluence.
Ribonuclease Protection Assay
Total RNA was extracted by the single-step guanidinium
thiocyanate-phenol-chloroform extraction method (Tri-
reagent; Molecular Research, Inc., Cincinnati, OH) after
cells were treated with TNF-
(20 ng/ml) (R&D Systems,
Minneapolis, MN) for 8 to 36 h. The RNA pellet was redissolved in diethylpyrocarbonate water after preciptation.
To construct the probe for CCSP mRNA, two sets of sense
and antisense primers (5' primer: 5'-CTCCACCATGAAACTCGCTG-3' [1-20]; 3' primer: 5'-GAAGAGAGCAAGGCTGGTGG-3' [367-348] [Bio-Synthesis, Inc., Lewisville,
TX]) were used to amplify a 367-base pair (bp) product of
CCSP complementary DNA (cDNA) by polymerase chain
reaction (PCR). The 367-bp CCSP gene product was then
cloned into the TA cloning vector (Invitrogen, San Diego,
CA) and orientation of the insert was determined by DNA
sequencing. RNA probes for the CCSP and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were prepared by in vitro transcription using T7 polymerase with
[
-32P] cytidine triphosphate. A ribonuclease (RNase) protection assay (RPA) kit (RPAII; Ambion, Austin, TX)
was used for the experiment. Hybridization was performed
at 45°C for 16 h with 10 µg (for GAPDH) or 50 µg (for
CCSP) of total RNA and 104 cpm (for GAPDH) and 2 × 104 cpm (for CCSP) of 32P-labeled RNA probe. A mixture
of 1:100 dilution of RNase A/ T1 was added to digest the
unhybridized RNA at 37°C for 60 min following hybridization. RNase inactivation and precipitation mixture was used to terminate the digestion. The protected RNA fragment was analyzed by autoradiography after separation on
6% polyacrylamide/8 M urea gels.
Western Blot Immunoassay
The supernatant medium from control and TNF-
(1, 10, 20, or 40 ng/ml) (R&D Systems) -treated BEAS-2B cells
was collected after cells were treated for 8 or 18 h. Proteinase inhibitors (proteinase inhibitor cocktail tablet; Boehringer Mannheim, Indianapolis, IN) were added to media
supernatant to avoid protein degradation. After dialysis in
3,500 mol wt tubing (Baxter, McGaw Park, IL) against distilled water, 100 ml supernatant was concentrated to 0.5 ml
by lyophilization. Total protein was assayed by BCA reagent (Pierce, Rockford, IN). Samples containing 10 µg total
protein were subjected to 18% Tris-Glysine gels (Novex,
San Diego, CA) under reducing conditions. NHTBE cells
grown in six-well dishes were divided as control and treated
cells. The supernatant medium from control cells and TNF-
(20 ng/ml) -treated cells was collected after NHTBE cells
were treated for 18 h. Proteinase inhibitors (proteinase inhibitor cocktail tablet; Boehringer Mannheim) were added
to media supernatant to avoid protein degradation. After dialysis in 3,500 mol wt tubing (Baxter) against distilled water, 6 ml supernatant was concentrated to 60 µl by lyophilization. Samples containing 30 µg total protein were
subjected to 18% Tris-Glysine gels (Novex) under reducing conditions. The separated proteins were electrophoretically transferred onto a nitrocellulose membrane (Schleicher & Schuell, Keene, NH) and blocked with 5% nonfat
dry milk overnight. CCSP protein expression was detected
by a 1:500 dilution of rabbit-antihuman CC10 polyclonal antibody (a generous gift from Dr. Gurmukh Singh, Laboratory Service, V.A. Medical Center, Pittsburgh, PA) and
a 1:5,000 dilution of horseradish peroxidase-conjugated
goat-antirabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) as second antibody, using the
ECL western blotting detection system (Amersham Corp.,
Arlington Heights, IL).
Plasmid Construction
Two constructs containing the 5'-flanking sequences of
CCSP gene were generated by PCR from a human genomic DNA library. PCR primers derived from published
sequences are as follows. A 24-mer 3' primer containing a
BglII restriction site at its 5' end (5'-GAAGATCTTCTCTGGTTCCGTTCTCTG-3') was used for both constructs,
which corresponds from +31 to +13 of human CCSP gene
sequence. Two 5' primers were constructed to generate different deletion constructs. Each 5' primer contains a 5'
KpnI site and started at either
801 (5'-GGGGTACCAGAATAAACATCTAAAGA-3'), or
168 (5'- GGGGTACCTGGGGACAGAAACTGGGT-3'). The PCR products were then ligated into PCR 2.1 (Invitrogen) vector.
The identity of the inserts and the fidelity of the PCR reaction was confirmed by DNA sequencing. The different truncated promoters (
801 to +31 and
168 to +31) were
then cloned into the multiple cloning site upstream of the
firefly luciferase coding region in the PGL3-basic vector
(Promega, Madison, WI).
Transient Plasmid Transfections
BEAS-2B cells were seeded in six-well plates and maintained at 37°C under 5% CO2 in LHC-8 medium (Biofluids) for each transfection experiment. Transfection was
done when cells reached 80% confluence with 2 µg of indicated reporter plasmid DNA using 12 µl of the Lipofectamine Reagent (Life Technologies, Gaithersburg, MD).
At the same time, 0.2 µg of a SEAP (secreted alkaline phosphatase, pCMV/SEAP) plasmid (Tropix, Bedford, MA) was
cotransfected as a control for transfection efficiency. Fresh
medium was added to cells, which were then incubated for
16 h after a 2-h transfection period. The cells were treated
with TNF-
(20 ng/ml) for 8 or 18 h. Transfected cells were
harvested and lysed, and extracts were evaluated for luciferase activity using luciferase assay reagent (Promega)
in a luminometer (Model 2010; Analytical Luminescence Laboratories, Ann Arbor, MI). Secreted alkaline phosphatase activity was assayed in culture media using a phospha-light kit (Tropix).
Nuclear Run-on Assay
Nuclear run-on assay was performed using a modification
of previously described methods (41, 42). Cells were stimulated with TNF-
(20 ng/ml) for 0, 0.5, 2, and 4 h and harvested after digestion with 0.1% collagenase in Hanks'
balanced salt solution (HBSS)(
) for 10 min. The cell pellet was washed with cold HBSS(
) and resuspended with
4 ml lysis buffer (10 mM Tris-buffered saline, 0.5% Nonidet P-40, 100 µg/ml leupeptin, 50 µg/ml aprotinin, 1 mM
dithiothreitol [DTT], 0.5 mM phenylmethylsulfonyl fluoride) and incubated on ice for 5 min. The nuclei were isolated by centrifuging at 500 × g for 5 min and washing with
1 ml lysis buffer. The nuclei were resuspended with 200 µl
of reaction buffer (10 mM Tris-HCl [pH 8.0]; 5 mM MgCl2;
300 mM KCl; 1 mM DTT; 0.5 mM each of ATP, CTP, and
GTP; and 200 µCi of [
-32P] UTP [3,000 Ci/mmol]; Amersham) and incubated at 30°C for 1 h. RNA was extracted
by the single-step guanidinium thiocyanate-phenol-chloroform extraction method with addition of 100 µg of yeast
transfer RNA. The samples were resuspended to equal
counts per minute per milliliter (5-6 × 106 dpm/ml) in hybridization buffer (50 mM [1,4-piperazinebis (ethane sulfonic acid)], pH 6.8; 10 mM ethylenediaminetetraacetic
acid; 600 mM NaCl; and 0.2% SDS). Hybridization to excess amounts (10 µg) of denatured CCSP and GAPDH
plasmid DNAs slot-blotted on nitrocellulose filters were
performed at 65°C for 40 h after prehybridizing at 70°C for
2 h in hybridization buffer containing 1% SDS. The DNA targets included the linearized plasmid PCR II containing
human CCSP cDNA and GAPDH as an internal control
or the plasmid PCR II as a negative control. By the end of
hybridization, the filters were washed in 2× standard saline citrate (SSC)/0.2% SDS, 1× SSC/0.2% SDS, and 0.5×
SSC/0.1% SDS, respectively, at 65°C for 1 h, and evaluated by autoradiography.
CCSP mRNA Half-life Assay in BEAS-2B Cells
For the determination of CCSP mRNA half-life of control
or treated cells, cells were stimulated with TNF-
(20 ng/
ml) for 18 h prior to the addition of actinomycin D (50 µg/
ml) (Calbiochem, San Diego, CA). Total RNA was extracted from cells at 0, 8, 18, and 24 h after the addition
of actinomycin D. RPAs were performed as described
above. The protected fragments were quantitated by using
a densitometer (Molecular Dynamics, Sunnyvale, CA). The quantity of CCSP mRNA was normalized to the amount of
GAPDH by calculating a CCSP/GAPDH ratio for each
sample. All time points were performed in triplicate.
| |
Results |
|---|
|
|
|---|
TNF-
Induced Increases in CCSP
Steady-State mRNA Levels
The steady-state levels of CCSP mRNA in control and
TNF-
-treated cells were measured by RPA. Whereas
CCSP mRNA was detectable in unstimulated cells, as
shown in Figure 1, TNF-
(20 ng/ml) induced a time-
dependent increase in steady-state CCSP mRNA levels over 8 to 36 h. As shown in Figure 2, TNF-
also induced
dose-dependent increases in steady-state CCSP mRNA
levels. RPAs for CCSP mRNA were performed after cells
were incubated with 1 to 40 ng/ml of TNF-
for 24 h. Although TNF-
at a concentration of 1 ng/ml had no effect, TNF-
in concentrations of 10 to 40 ng/ml induced
dose-dependent increases in CCSP mRNA levels.
|
|
TNF-
Induced Increases in Production and
Release of CCSP Protein
To determine the effect of TNF-
on CCSP protein production and release into the culture supernatant, Western
blots of culture supernatants prepared from control and
TNF-
-treated human bronchial epithelial (BEAS-2B)
cells and NHTBE cells were performed. TNF-
(20 ng/ml)
treatment increased the release of CCSP immunoreactive material into the supernatant in cultured BEAS-2B cells at
both 8 and 18 h (Figure 3). TNF-
also induced the release
of CCSP immunoreactive material into the supernatant in
cultured NHTBE cells after 18 h of treatment (Figure 4).
This material had an apparent molecular size of 7 kD on
SDS-PAGE.
|
|
The TNF-
-Mediated Increases in CCSP mRNA Were
Regulated at the Post-Transcriptional Level
The mechanism underlying the TNF-
-mediated increase
in CCSP mRNA in human airway epithelial cells was assessed in three different ways. First, the investigation of
CCSP promoter activation by TNF-
was assessed by
transfecting two separate reporter gene constructs into
BEAS-2B cells, followed by stimulation with TNF-
(20 ng/ml). The constructs "
168 Luc" and "
801 Luc" contain different 5' upstream sequences of the CCSP promoter and correspond to bases
168 to +31 or
801 to
+31. As shown in Figure 5, although both reporter gene
constructs exhibited promoter activities, TNF-
treatment
for 8 or 18 h did not enhance luciferase expression as compared with untreated control cells. Second, nuclear run-on assays were performed to study the change in transcriptional activity of the CCSP gene following TNF-
stimulation. TNF-
treatment for 0.5 to 4 h did not increase the
nuclear transcription rate of the CCSP gene (Figure 6).
Finally, because both transcriptional assays did not suggest transcriptional regulation of the observed changes in
steady-state CCSP mRNA levels, we studied CCSP mRNA half-life. CCSP mRNA levels were analyzed by RPA after
total RNA was extracted from actinomycin D-treated cells
which were first stimulated with either control media or
TNF-
(20 ng/ml). As shown in Figure 7, TNF-
-stimulated
cells displayed a prolonged CCSP mRNA half-life as compared with unstimulated cells. The calculated half-life of
CCSP mRNA in control cells was 16 h, whereas the calculated half-life of CCSP mRNA in the TNF-
-treated cells
was prolonged to 64 h (P < 0.01, n = 3 by analysis of variance). These results suggest that TNF-
induces CCSP
gene expression in airway epithelial cells through a post-transcriptional regulatory mechanism.
|
|
|
| |
Discussion |
|---|
|
|
|---|
The human CCSP gene is a single-copy gene expressed in airway epithelial cells, among other tissues (1, 2, 6, 12, 18, 19). In vitro, CCSP has been shown to inhibit secretory PLA2 (sPLA2) and porcine pancreatic PLA2 (22, 43), which are esterases that hydrolyze the sn-2 ester bonds in phosphoglyceride molecules, releasing a free fatty acid and lysophospholipids. These products may themselves serve as messengers (44) or they can be further metabolized to prostaglandins, hydroxyeicosatetraenoic acids, and leukotrienes, potent lipid mediators of inflammation (45). Human CCSP is capable of complexing with transglutaminase, which can also suppress the antigenicity of foreign proteins (46). It has been reported that CCSP has an inhibitory control over cPLA2 activity in lung fibroblasts in vitro (47). CCSP is able to inhibit fibroblast chemotaxis in vitro by mechanisms that may be related to inhibition of PLA2 activity. Thus, reduced CCSP might contribute to fibroblast activity in fibrosing lung disease (47). Significantly higher levels of CCSP have also been observed in bronchoalveolar lavage fluid from patients with acute lung injury (48). The inhibition of PLA2 activity by CCSP may be important in controlling inflammatory activity in the lung by reducing arachidonic acid available for metabolism to active metabolites.
The results of our experiments indicate that human bronchial epithelial cells in culture can synthesize and secrete CCSP. In this case, two human bronchial epithelial cell lines (BEAS-2B and NHTBE cells) were used for the study of CCSP expression. We used a rabbit-antihuman CC10 polyclonal antibody utilized in previous studies (2, 18) for detection of CCSP by Western blotting. We found that the secreted CCSP migrated on SDS-PAGE under reducing conditions with an apparent molecular mass of about 7 kD. This observation is in agreement with the protein size reported by Jorens and associates (48) and Bernard and coworkers (49). Their results showed that the unreduced CCSP homodimer has a molecular mass of 15.8 kD by electro-spray/mass spectrometry and a mass of 7.8 kD under reducing conditions.
The ability of TNF to affect the growth, differentiation,
and other functions of a variety of cell types relies to a
great extent on the potent gene regulatory properties of
TNF (29, 39). Interaction of TNF with its receptors induces the expression of a number of cellular genes in various
cell types. Although the induction of many TNF-responsive genes is mediated at the transcriptional level, the expression of some genes is regulated by TNF at the post-transcriptional level (50, 51, 52). In our present study, we
observed an increase of steady-state CCSP mRNA in parallel with increased CCSP protein production by human bronchial epithelial cells after TNF-
stimulation. There
are three areas in the 5' promoter region of the CCSP
gene that represent putative AP1 sites which might be effected by TNF stimulation. These sites are at
273 (6/7
nucleotides),
413 (6/7 nucleotides), and
540 (6/7 nucleotides). Although the
801 to +31 reporter gene construct contained all of these putative AP1 sites, the luciferase activity measured in the reporter gene construct
did not increase after TNF-
treatment. In contrast, our
study showed a continued increase of CCSP mRNA after
8 to 36 h of treatment with TNF-
with no transcription-rate increase. In addition, a significant change in CCSP
mRNA half-life was measured. Therefore, our results suggest that the TNF-
-mediated increases in CCSP gene expression are regulated at least in part at the post-transcriptional level.
Studies of the glucose transporter (GLUT1) mRNA
stability suggest a mechanism via which TNF-
regulates,
at the post-transcriptional level, increases in steady-state
mRNA levels. TNF stimulation of 3T3-L1 preadiposites
results in the prolongation of mRNA half-life of the GLUT1
gene product. GLUT1 mRNA contains a AUUUA message destabilization motif in the 3'UTR. TNF induces expression of proteins which bind to the 3'UTR of the GLUT1
message, perhaps masking the AUUUA sequence and
therefore prolonging GLUT1 mRNA half-life (52). CCSP
mRNA also contains an AUUUA sequence in the 3'UTR
which might serve a similar function. One might speculate that the effect of TNF on the CCSP message might be mediated by induced RNA binding proteins which prolong
message stability.
TNF has been reported to induce the synthesis and secretion of Type II secreted PLA2 from alveolar macrophage cells (51). Furthermore, the production of sPLA2 by
alveolar macrophages in response to endotoxin is also TNF-dependent (53). The subsequent production of CCSP by
airway epithelial cells in response to TNF stimulation suggests a counterregulatory mechanism by which proinflammatory cytokines, such as TNF, might stimulate inflammatory cell production of sPLA2 and subsequently stimulate
epithelial-cell production of CCSP. This series of events
could allow for the localized induction of an inflammatory
response with the subsequent protection of the airway epithelium and attenuation of the TNF-induced inflammatory process in the airway lumen. In summary, we have demonstrated that TNF-
can upregulate both CCSP gene expression and protein synthesis in human airway epithelial
cells and in this way it may modulate airway inflammation.
| |
Footnotes |
|---|
Address correspondence to: J. H. Shelhamer, M.D., Bldg. 10, Rm. 7-D-43, NIH, Bethesda, MD 20892.
(Received in original form August 5, 1997 and in revised form February 2, 1998).
Abbreviations CCSP, Clara cell secretory protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NHTBE cells, normal human tracheobronchial epithelial cells; PLA2, phospholipase A2; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TNF, tumor necrosis factor.
| |
References |
|---|
|
|
|---|
1. Hackett, B. P., N. Schimizu, and J. D. Gitlin. 1992. Clara cell secretory protein gene expression in bronchiolar epithelium. Am. J. Physiol. 262: 2399-2404 .
2. Singh, G., J. Singh, S. L. Katyal, W. E. Brown, J. A. Kramps, I. L. Paradis, J. H. Dauber, T. A. Macpherson, and N. Squeglia. 1988. Identification, cellular localization, isolation and characterization of human Clara cell-specific 10 kD protein. J. Histochem. Cytochem. 36: 73-78 [Abstract].
3.
Hagen, G.,
M. Wolf,
S. L. Katyal,
G. Singh,
M. Beato, and
G. Suske.
1990.
Tissue-specific expression, hormonal regulation and 5'-flanking gene region of the rat Clara cell 10 kDa protein: comparison to rabbit uteroglobin.
Nucleic Acids Res.
18:
2939-2946
4.
Nordlund-Moller, L.,
O. Anderson,
R. Ahlgren,
J. Skilling,
M. Gillner,
J. Gustafsson, and
J. Lund.
1990.
Cloning, structure, and expression of a rat
binding protein for polychlorinated biphenyls.
J. Biol. Chem.
265:
12690-12693
5. Singh, G., S. L. Katyal, W. E. Brown, and A. L. Kennedy. 1993. Mouse Clara cell 10kDa (CC10) protein: cDNA nucleotide sequence and molecular basis for the variation in progesterone binding of CC10 from different species. Exp. Lung Res. 19: 67-75 [Medline].
6. Singh, G., S. L. Katyal, J. M. Ward, S. A. Gottron, M. L. Wong-Chong, and E. J. Riley. 1985. A secretory protein of the lung in rodents: immunocytochemistry. J. Histochem. Cytochem. 33: 564-568 [Abstract].
7.
Suske, G.,
M. Wenz,
A. Cato, and
M. Beato.
1983.
The uteroglobin gene region: hormonal regulation, repetitive elements and complete nucleotide
sequence of the gene.
Nucleic Acids Res.
11:
2257-2271
8. Lund, J., L. Nordlund, and J. Gustafsson. 1988. Partial purification of a binding protein for polychlorinated biphenyls from rat lung cytosol: physiochemical and immunochemical characterization. Biochemistry 27: 7895-7901 [Medline].
9. Bernard, A., H. Roels, R. Lauwerys, R. Witters, C. Gielens, A. Soumillion, J. Damme, and M. De Ley. 1992. Human urinary protein 1: evidence for identity with the Clara cell protein and ocurrence in respiratory tract and urogenital secretions. Clin. Chim. Acta 207: 239-249 [Medline].
10. Morize, I., E. Surcouf, M. C. Vaney, Y. Epelboin, M. Buehner, F. Fridlansky, E. Milgrom, and J. P. Mornon. 1987. Refinement of the C2221 crystal form of oxidized uteroglobin at 1.34Å resolution. J. Mol. Biol. 194: 725-739 [Medline].
11. Bally, R., and J. Delletre. 1989. Structure and refinement of the oxidized P21 form of uteroglobin at 1.64Å resolution. J. Mol. Biol. 206: 153-170 [Medline].
12. Andersson, O., L. Nordlund-Moller, M. Bronnegard, F. Sirzea, E. Ripe, and J. Lund. 1991. Purification and level of expression in bronchoalveolar lavage of a human polychlorinated biphenyl (PCB)-binding protein evidence for a structural and functional kinship to the multihormonally regulated protein uteroglobin. Am. J. Respir. Cell Mol. Biol. 5: 6-21 .
13. Ray, M. K., S. Magdaleno, B. O'Malley, and F. DeMayo. 1993. Cloning and characterization of the mouse Clara cell specific 10 kDa protein gene: comparison of the 5'-flanking region with human rat and rabbit gene. Biochem. Biophys. Res. Commun. 197: 163-171 [Medline].
14. Singh, G., S. L. Katyal, W. E. Brown, A. L. Kennedy, U. Singh, and M. L. Wong-Chong. 1990. Clara cell 10kDa protein. Biochim. Biophys. Acta 1039: 348-355 [Medline].
15. Singh, G., S. L. Katyal, W. E. Brown, S. Philips, A. L. Kennedy, J. Anthony, and N. Squeglia. 1988. Amino-acid and cDNA nucleotide sequences of human Clara cell 10 kDa protein. Biochim. Biophys. Acta 950: 329-337 [Medline].
16. Peri, A., E. Cordella-Miele, L. Miele, and A. B. Mukherjee. 1993. Tissue-specific expression of the gene coding for human CC10 kDa, a phospholipase A2 inhibitory protein. J. Clin. Invest. 92: 2099-2109 .
17.
Wolf, M.,
J. Klug,
R. Hackenberg,
M. Gessler,
K. H. Grzeschik,
M. Beato, and
G. Suske.
1992.
Human CC10, the homologue of rabbit uteroglobin:
genomic cloning, chromosomal localization and expression in endometrial
cell lines.
Human Mol. Gen.
1:
371-378
18. Singh, G., and S. L. Katyal. 1984. An immunological study of the secretory products of rat Clara cells. J. Histochem. Cytochem. 32: 49-54 [Abstract].
19. Singh, G., S. Singal, S. L. Katyal, W. E. Brown, and S. A. Gottron. 1987. Isolation and amino acid composition of the isotope of a rat Clara cell specific protein. Exp. Lung Res. 13: 299-309 [Medline].
20.
Hay, J.,
C. Daniel,
C. S. Chu, and
R. G. Crystal.
1995.
Human CC10 gene
expression in airway epithelium and subchromosomal locus suggest linkage to airway disease.
Am. J. Physiol.
268:
L565-L575
21. Katyal, S. L., G. Singh, W. E. Brown, A. L. Kennedy, N. Squeglia, and M. Wong-Chong. 1990. Clara cell secretory (10kDa) protein: amino acid and cDNA nucleotide sequences and developmental expression. Prog. Respir. Res. 25: 29-35 .
22.
Andersson, O.,
L. Nordlund-Moller,
H. Barnes, and
J. Lund.
1994.
Heterologous expression of human uteroglobin/polychlorinated biphenyl-binding
protein.
J. Biol. Chem.
269:
19081-19087
23.
Zhang, Z.,
G. Kundu,
C. Yuan,
J. Ward,
E. Lee,
F. DeMayo,
H. Westphal, and
A. Mukherjee.
1997.
Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin.
Science
276:
1408-1412
24. Davidson, F. F., and E. A. Dennis. 1989. Biological relevance of lipocortins and related proteins as inhibitors of phospholipase A2. Biochem. Pharmacol. 38: 3645-3651 [Medline].
25.
Mantile, G.,
L. Miele,
E. Cordella-Miele,
G. Singh,
S. L. Katyal, and
A. B. Mukherjee.
1993.
Human Clara cell 10-kDa protein is the counterpart of
rabbit uteroglobin.
J. Biol. Chem.
268:
20343-20351
26. Thompson, A. B., R. A. Robbins, and D. J. Romberger. 1995. Immunological functions of the pulmonary epithelium. Eur. Respir. J. 8: 127-149 [Abstract].
27. Rennard, S. I., J. D. Beckmann, and R. A. Robbins. 1991. Biology of airway epithelial cells. In The Lung Scientific Foundations. R. G. Crystal and J. B. West, editors. Raven Press, New York. 157-167.
28.
Vilcek, J., and
T. H. Lee.
1991.
Tumor necrosis factor: new insights into the
molecular mechanisms of its multiple actions.
J. Biol. Chem.
266:
7313-7316
29. Fiers, W.. 1991. Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett. 285: 199-212 [Medline].
30. Pfizenmaier, K., A. Himmler, S. Schutze, P. Scheurich, and M. Kronke. 1992. TNF receptors and TNF signal transduction. In Tumor Necrosis Factor: The Molecules and Their Emerging Role in Medicine. B. Beutler, editor. Raven Press, Ltd., New York. 439-472.
31. Kronke, M., S. Schutze, P. Scheurisch, and K. Pfizenmaier. 1992. TNF signal transduction and TNF-responsive genes. In Tumor Necrosis Factors: Structure, Function and Mechanism of Action. B. Aggarwal and J. Vilcek, editors. Marcel Dekker, Inc., New York. 189-216.
32.
Cammussi, G.,
E. Albano,
C. Tetta, and
F. Bussolio.
1991.
The molecular
action of tumor necrosis factor-
.
Eur. J. Biochem.
202:
3-14
[Medline].
33.
Palomebella, V. J., and
J. Vilcek.
1989.
Mitogenic and cytotoxic actions of
tumor necrosis factor in Balb/c 3T3 cells.
J. Biol. Chem.
264:
18128-18136
34. Knauer, M. F., K. J. Longmuir, R. S. Yamamoto, T. P. Fitzgerald, and G. A. Granger. 1990. Mechanism of human lymphotoxin and tumor necrosis factor induced destruction of cells in vitro: phospholipase activation and deacylation of specific membrane phospholipids. J. Cell. Physiol. 142: 469-479 [Medline].
35. Clark, M. A., M. J. Chen, S. T. Crooke, and J. S. Bomalaask. 1988. Tumor necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. Biochem. J. 250: 125-132 [Medline].
36. Hori, T., S. Kashhiyama, M. Hayakawa, S. Sibamoto, M. Tsujimoto, N. Oku, and F. Ito. 1989. Possible role of prostaglandins as negative regulators in growth stimulation by tumor necrosis factor and epidermal growth factor in human fibroblasts. J. Cell. Physiol. 141: 275-280 [Medline].
37. Hoeck, W. G., C. S. Ramesha, D. J. Chang, N. Fan, and A. R. Heller. 1993. Cytoplasmic phospholipase A2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis. Biochemistry 90: 4475-4479 .
38.
Wu, T.,
S. J. Levine,
M. G. Lawrance,
C. Logun,
W. Angus, and
J. H. Shelhamer.
1994.
Interferon-
induces the synthesis and activation of cytosolic
phospholipase A2.
J. Clin. Invest.
93:
571-577
.
39.
Oka, S., and
H. Arita.
1991.
Inflammatory factors stimulate expression of
group II phospholipase A2 in rat cultured astrocytes: two distinct pathways
of the gene expression.
J. Biol. Chem.
266:
9956-9960
40.
Crow, R. M.,
T. J. Stoller,
R. R. Conroy, and
C. R. Stoner.
1991.
Induction
of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.
J. Biol. Chem.
266:
2647-2651
41. Greenberg, M. E., and E. B. Ziff. 1984. Stimulation of 3t3 cells induces transcription of the c-fos proto-oncogene. Nature 311: 433-438 [Medline].
42.
Kavanaugh, W. M.,
G. R. Harsh,
N. F. Starksent,
C. M. Rocco, and
L. T. Williams.
1988.
Transcriptional regulation of the A and B chain genes of
platelet-derived growth factor in microvascular endothelial cells.
J. Biol.
Chem.
263:
8470-8472
43. Miele, L., E. Cordella-Miele, A. Facchiano, and A. B. Mukherjee. 1988. Novel anti-inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I. Nature 335: 726-729 [Medline].
44. Liscovitch, M., and L. C. Cantley. 1994. Lipid second messengers. Cell 77: 329-334 [Medline].
45. Holtzman, M. J.. 1991. Arachidonic acid metabolism. Implications of biological chemistry for lung function and disease. Am. Rev. Respir. Dis. 143: 188-203 [Medline].
46. Manjunath, M., S. I. Chung, and A. B. Mukherjee. 1984. Crosslinking of uteroglobin by transglutaminase. Biochem. Biophys. Res. Commun. 121: 400-405 [Medline].
47. Lesur, O., A. Bernard, K. Arsalane, R. Lauwerys, R. Begin, A. Cantin, and D. Lane. 1995. Clara cell protein (CC16) induces a phospholipase A2- mediated inhibition of fibroblast migration in vitro. Am. J. Respir. Crit. Care Med. 152: 290-297 [Abstract].
48. Jorens, P. G., Y. Sibille, N. J. Goulding, F. J. Van Overveld, A. G. Herman, L. Bossaert, W. A. De Backer, R. Lauwerys, R. J. Flower, and A. Bernard. 1995. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur. Respir. J. 8: 1647-1653 [Abstract].
49. Bernard, A., X. Dumont, H. Roels, R. Lauwerys, I. Dierynck, M. De Ley, V. Stroobant, and E. De Hoffmann. 1993. The molecular mass and concentrations of protein 1 or Clara cell protein in biological fluids: a reappraisal. Clin. Chim. Acta 223: 189-191 [Medline].
50.
Koeffler, H. P.,
J. Gasson, and
A. Tobler.
1988.
Transcriptional and post-transcriptional modulation of myeloid colony-stimulating factor expression by tumor necrosis factor and other agents.
Mol. Cell. Biol.
8:
3432-3438
51. Sherman, M. L., B. L. Weber, R. Datta, and D. W. Kufe. 1990. Transcriptional and posttranscriptional regulation of macrophage-specific colony stimulating factor gene expression by tumor necrosis factor: involvement of arachidonic acid metabolites. J. Clin. Invest. 85: 442-447 .
52.
McGowan, K.,
S. Police,
J. Winslow, and
P. Pekala.
1997.
Tumor necrosis
factor-
regulation of glucose transporter (GLUT1) mRNA turnover.
J.
Biol. Chem.
272:
1331-1337
53. Aribe, L., D. Vial, I. Rosinski-Chupin, N. Havet, M. Huerre, B. Vargaftig, and L. Toqui. 1997. Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs. J. Immunol. 159: 391-400 [Abstract].
This article has been cited by other articles:
![]() |
J. Chen, S. Lam, A. Pilon, A. McWilliams, C. MacAulay, and E. Szabo Higher Levels of the Anti-inflammatory Protein CC10 Are Associated with Improvement in Bronchial Dysplasia and Sputum Cytometric Assessment in Individuals at High Risk for Lung Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1590 - 1597. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Grubor, D. K. Meyerholz, and M. R. Ackermann Collectins and cationic antimicrobial peptides of the respiratory epithelia. Vet. Pathol., September 1, 2006; 43(5): 595 - 612. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Janssen, H. Sato, J. C. Grutters, H. J. T. Ruven, R. M. du Bois, R. Matsuura, M. Yamazaki, S. Kunimaru, T. Izumi, K. I. Welsh, et al. The Clara Cell10 Adenine38Guanine Polymorphism and Sarcoidosis Susceptibility in Dutch and Japanese Subjects Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1185 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. Ramsay, Z. Luo, S. M. Magdaleno, S. K. Whitbourne, X. Cao, M. S. Park, S. E. Welty, L.-Y. Yu-Lee, and F. J. DeMayo Transcriptional regulation of CCSP by interferon-gamma in vitro and in vivo Am J Physiol Lung Cell Mol Physiol, January 1, 2003; 284(1): L108 - L118. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kim, J. J. Shim, P.-R. Burgel, I. F. Ueki, T. Dao-Pick, D. C.-W. Tam, and J. A. Nadel IL-13-induced Clara cell secretory protein expression in airway epithelium: role of EGFR signaling pathway Am J Physiol Lung Cell Mol Physiol, July 1, 2002; 283(1): L67 - L75. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Harrod and R. J. Jaramillo Pseudomonas aeruginosa and Tumor Necrosis Factor-alpha Attenuate Clara Cell Secretory Protein Promoter Function Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 216 - 223. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Watson, S. D. Reynolds, G. W. Mango, I.-M. Boe, J. Lund, and B. R. Stripp Altered lung gene expression in CCSP-null mice suggests immunoregulatory roles for Clara cells Am J Physiol Lung Cell Mol Physiol, December 1, 2001; 281(6): L1523 - L1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hayashida, K. S. Harrod, and J. A. Whitsett Regulation and function of CCSP during pulmonary Pseudomonas aeruginosa infection in vivo Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L452 - L459. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |